Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children and young people who are under 18 years old at the time of joining the study.
- People who have been newly diagnosed with a type of blood cancer called acute myeloid leukaemia (AML), based on 2022 international diagnostic guidelines, with or without the cancer spreading to other parts of the body.
- People whose bone marrow test shows a certain level of abnormal cancer cells (called blasts), or where a blood test shows a high enough level of these cells if a bone marrow test is not safe or possible.
- In Malawi specifically, where some specialist tests are not available, a treating cancer doctor may include a patient with lower blast levels if they document their reasoning (confirm with trial site).
- People who are starting treatment following a specific 2023 treatment guideline used at the trial site (KCH AML therapy CPG).
Who may not be able to join:
- People diagnosed with a related but different blood condition called juvenile myelomonocytic leukaemia.
- People with a temporary blood cell disorder called transient myeloproliferative disorder.
- People with a specific subtype of leukaemia called acute promyelocytic leukaemia.
- People with a leukaemia that involves more than one blood cell type (mixed phenotype acute leukaemia).
- People who have Down syndrome (Trisomy 21).
- People who are currently pregnant.
- People who have had, or currently have, another type of cancer.
- People whose cancer appears only as a tumour outside the bone marrow, without other signs of AML (isolated myeloid sarcoma).
- People who have already received cancer-fighting treatments, except for the following, which are allowed: hydroxyurea, corticosteroids (steroid medicines), or chemotherapy given directly into the spinal fluid at the time of diagnosis.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Casey McAtee, M.D., M.P.H., Baylor College of Medicine
Phone: +1 251-605-5370
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the implementation success of an intensity adapted clinical practice guideline (CPG) based upon recommendations by the International Society of Paediatric Oncology (SIOP) for childhood AML in resource limited settings.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.